TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Risk of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation in measurement of corneal layers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodule malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thyrogonial distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pimecrolimus blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door-to-Needle Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Health Questionnaire-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Generalized Anxiety Disorder 7-item scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of uptake of male circumcision
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of Progenitor Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of blood glucose values within normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regional ventilation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Microbiological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects with Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Score on Reflux Symptom Index (RSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: P50 Percent Habituation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patient reported outcome score (IKDC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score at R-LAST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS score ≤ 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety, as assessed by any serial adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hip Osteoarthritis Outcomes Score (HOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accrual as measured by number of participants recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence as measured by completing all intervention sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attrition as measured by 80% participants completing the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability as measured by 80% participants reporting satisfaction with CST program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC+)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence/absence of treatment-requiring element
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients correctly sampled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Body fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstructive airway complication requiring intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 3-Year Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative patient reported signs and symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: safety profile and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of genetic variants associated with epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA Adducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in regional bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Best overall response rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving transpulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bohr dead space fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shunt fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventricular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scaled score on Verbal IQ tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall subjective comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Foot function index revised short (FFI-R short)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outcomes of hemorrhoidal surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dimension of the eyeball
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety and Depression on HADS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Happiness on Lima happiness questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Trial Making Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Presence of malaria parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fraction of isolates of pneumococcus exhibiting macrolide resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Height over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of HV evaluated by foot pressure platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of gastric and duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of GI-Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rebleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sufficient Collection of Hemopoietic Stem Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Performance of colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of SF600 forms not supporting vaccination decision
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients With Primary Lesions Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Nodal Metastases Detected on Fluciclovine-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of the course of the left vein and location of the phrenic nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delayed hematologic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in HAD total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in CGI scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of postspinal hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Incidents of Wound Complications 30-days Post-Op
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with a related serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with newly acquired transmissible infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with a related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: changes from baseline in mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes from baseline in hedonic wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes from baseline in satisfaction with life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of successful study periods with no circuit-clotting event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in ADHD-Rating Scale 5 (ADHD-RS-5) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood Pressure (BP) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving treatment goals for HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving treatment goals for blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving treatment goals for total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite Staff Evaluation Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-rated degree of patient participation in rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Overall Clinical Benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of T cells expressing PD-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinity, AUC (INF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With a Positive Result in Absolute QT Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of bronchiolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Health of Nations Outcome Scale (HoNOS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Morphological effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Procedural success and freedom from FIRE1 sensor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cohort A1 Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cohort A1 Duration of response (DOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: State Trait Anxiety Inventory Y-1
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: visual analogic scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and type of injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (CR or PR) Prior to Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels of IgG in the serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with increase of total medium FAM test score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of drug related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Errors made during the task at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Errors made during the task at proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of training (in euro)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fertility Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: beta-cell glucose sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Annual Rate of Change in Lung Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Complete the 12 Week Assessment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of women developed vaginal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of poor global deterioration scale (GDS) at 1 month after CO exposure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of poor global deterioration scale (GDS) at 6 months after CO exposure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nasal reaction threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of serious fallers included in the geriatric pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall hematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of nasal IMV and CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Numeric Rating Scale (NRS) Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: biliary stricturer rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cholangitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients without disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment-upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of Ferritin in GCF and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of ALP in GCF and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human milk oligosaccharide detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Suppression of Herpes Simplex Virus Replication (Shedding Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fetal head position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 and 18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospital admissions or death
Endpoint domain: Mortality/survival
Primary endpoint: gap density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMT of anti-EV71 antibodies in serum after first vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of anti-EV71 antibodies in serum after second vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of systemic and local adverse reactions after the first vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of systemic and local adverse reactions after the second vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of signs and symptoms of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the degree of enjoyment and satisfaction in areas of daily functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in appearance satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in functionality satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in body appreciation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Endpoint domain: Adverse events/effects
Primary endpoint: Atomoxetine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of neutrophils in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in concentration of total protein in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early language assessment at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Early language assessment at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Receptive vocabulary assessment at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Infant Body Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time required for discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: non-hypoxic apnoeic period (time to fall SpO2 to 92%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores with Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Checklist - Stressor Specific (PCL-S) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of time spent within sedation range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RC /SPECT/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Distress - Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pain Inventory
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Self Assessed Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Polycystic Liver Disease Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in the Global Acne scarring classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with moderate to severe injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Barthel Index (activities of daily living)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain assessment change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Coronary Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTcF Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in elastin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hyaluronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Vortx Rx
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of specific clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum lipoproteins analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average distance to central point of the target cardiovascular zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All-cause mortality during hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes